Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

PHASE4TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

July 4, 2024

Study Completion Date

July 4, 2024

Conditions
Inflammatory Bowel Diseases
Interventions
BIOLOGICAL

SHINGRIX

"SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."

Trial Locations (1)

02118

Boston Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Boston Medical Center

OTHER